Suzanne Jenkins
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Journal: Targeted oncology
Published: March 27, 2023
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Journal: Investigational new drugs
Published: February 13, 2023
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: September 14, 2020
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 05, 2019
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 11, 2018
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 22, 2017
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 22, 2016
EGFR T790M mutation testing within the osimertinib AURA Phase I study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 06, 2016
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 13, 2015
High-throughput SNP genotyping.
Journal: Comparative and functional genomics
Published: November 12, 2001
Showing 1-11 of 11
Last Updated: 09/26/2026